These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33583424)

  • 1. Development and evaluation of an interactive web-based decision-making programme on relapse management for people with multiple sclerosis (POWER@MS2)-study protocol for a randomised controlled trial.
    Rahn AC; Wenzel L; Icks A; Stahmann A; Scheiderbauer J; Grentzenberg K; Vomhof M; Montalbo J; Friede T; Heesen C; Köpke S
    Trials; 2021 Feb; 22(1):139. PubMed ID: 33583424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An interactive web-based programme on relapse management for people with multiple sclerosis (POWER@MS2) - development, feasibility, and pilot testing of a complex intervention.
    Wenzel L; Heesen C; Peper J; Grentzenberg K; Faßhauer E; Scheiderbauer J; Thale F; Meyer B; Köpke S; Rahn AC
    Front Neurol; 2022; 13():914814. PubMed ID: 36212638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of an interactive web-based programme on relapse management for people with multiple sclerosis (POWER@MS2): study protocol for a process evaluation accompanying a randomised controlled trial.
    Wenzel L; Heesen C; Scheiderbauer J; van de Loo M; Köpke S; Rahn AC
    BMJ Open; 2021 Oct; 11(10):e046874. PubMed ID: 34598981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial.
    Rahn AC; Köpke S; Kasper J; Vettorazzi E; Mühlhauser I; Heesen C
    Trials; 2015 Mar; 16():106. PubMed ID: 25872529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nurse-led immunotreatment DEcision Coaching In people with Multiple Sclerosis (DECIMS) - Feasibility testing, pilot randomised controlled trial and mixed methods process evaluation.
    Rahn AC; Köpke S; Backhus I; Kasper J; Anger K; Untiedt B; Alegiani A; Kleiter I; Mühlhauser I; Heesen C
    Int J Nurs Stud; 2018 Feb; 78():26-36. PubMed ID: 28982479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study protocol for a randomised controlled trial of a web-based behavioural lifestyle programme for emPOWERment in early Multiple Sclerosis (POWER@MS1).
    Krause N; Riemann-Lorenz K; Steffen T; Rahn AC; Pöttgen J; Stellmann JP; Köpke S; Friede T; Icks A; Vomhof M; Temmes H; van de Loo M; Gold SM; Heesen C
    BMJ Open; 2021 Feb; 11(2):e041720. PubMed ID: 33593774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
    Gold R; Giovannoni G; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; Robinson R; Riester K; Rana J; Elkins J; O'Neill G;
    Lancet; 2013 Jun; 381(9884):2167-75. PubMed ID: 23562009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.
    Voskuhl RR; Wang H; Wu TC; Sicotte NL; Nakamura K; Kurth F; Itoh N; Bardens J; Bernard JT; Corboy JR; Cross AH; Dhib-Jalbut S; Ford CC; Frohman EM; Giesser B; Jacobs D; Kasper LH; Lynch S; Parry G; Racke MK; Reder AT; Rose J; Wingerchuk DM; MacKenzie-Graham AJ; Arnold DL; Tseng CH; Elashoff R
    Lancet Neurol; 2016 Jan; 15(1):35-46. PubMed ID: 26621682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial.
    Köpke S; Kasper J; Mühlhauser I; Nübling M; Heesen C
    Mult Scler; 2009 Jan; 15(1):96-104. PubMed ID: 18845657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)-a systematic review protocol.
    Lehnert T; Röver C; Köpke S; Rio J; Chard D; Fittipaldo AV; Friede T; Heesen C; Rahn AC
    Syst Rev; 2022 Jul; 11(1):134. PubMed ID: 35778721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MultiSCRIPT-Cycle 1-a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial.
    Janiaud P; Zecca C; Salmen A; Benkert P; Schädelin S; Orleth A; Demuth L; Maceski AM; Granziera C; Oechtering J; Leppert D; Derfuss T; Achtnichts L; Findling O; Roth P; Lalive P; Uginet M; Müller S; Pot C; Hoepner R; Disanto G; Gobbi C; Rooshenas L; Schwenkglenks M; Lambiris MJ; Kappos L; Kuhle J; Yaldizli Ö; Hemkens LG
    Trials; 2024 Sep; 25(1):607. PubMed ID: 39261900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
    Burton JM; O'Connor PW; Hohol M; Beyene J
    Cochrane Database Syst Rev; 2012 Dec; 12():CD006921. PubMed ID: 23235634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
    Le Page E; Veillard D; Laplaud DA; Hamonic S; Wardi R; Lebrun C; Zagnoli F; Wiertlewski S; Deburghgraeve V; Coustans M; Edan G; ;
    Lancet; 2015 Sep; 386(9997):974-81. PubMed ID: 26135706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Kappos L; Hartung HP; Freedman MS; Boyko A; Radü EW; Mikol DD; Lamarine M; Hyvert Y; Freudensprung U; Plitz T; van Beek J;
    Lancet Neurol; 2014 Apr; 13(4):353-63. PubMed ID: 24613349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.